Applied Molecular Therapies

Applied Molecular Therapies is an Australian radiopharmaceutical and theranostics company established as a joint venture between Cyclotek and ANSTO to develop, manufacture, and supply targeted cancer radiotherapies. The company was created to build TGA-approved GMP manufacturing capability in Australia for therapeutic radiopharmaceuticals, initially centered on Lutetium-177 products. Its first highlighted product has been 177Lu(n.c.a.)-PSMA-Therapy for prostate cancer, and it has also pursued 177Lutetium (nca) Octreotate for neuroendocrine and other somatostatin receptor-positive cancers. The business appears to operate primarily as a regional developer-manufacturer and supply platform for theranostic cancer agents in Australia and New Zealand rather than as a broad, traditional clinical-stage biotech pipeline company. AMT sits at the intersection of radiochemistry, nuclear medicine manufacturing, and oncology commercialization.